

DAFTAR PUSTAKA

- Hanzelina, H., Widnyana, A.A.N.K.P., Windiani, I.G.A.T., Karyana, I.P.G., Ariawati, N.K., Mahalini, D.S. (2022). Malnutrition as risk factor for febrile neutropenia in children with acute lymphoblastic leukemia. *Macedonian Journal of Medical Sciences*, 10 (B): 681–685. <https://doi.org/10.3889/oamjms.2022.8448>
- Agnes, M., Widjajanto, P.H., & Damayanti, W. (2018). Impact of malnutrition on febrile neutropenia in children with acute lymphoblastic leukemia during induction phase chemotherapy. *Paediatrica Indonesiana*, 58 (6): 298–304. <https://doi.org/10.14238/pi58.6.2018.298-304>
- Munteanu, C., Schwartz, B. (2022). The relationship between nutrition and the immune system. *Frontiers in Nutrition*. 10.3389/fnut.2022.10882500
- Lyman, GH, Morrison, VA, Dale, DC, Crawford, J., Delgado, DJ, & Fridman, M. (2003). Risiko Neutropenia Demam pada Pasien dengan Limfoma Non-Hodgkin Tingkat Menengah yang Menerima Kemoterapi CHOP. *Leukemia & Limfoma*, 44 (12), 2069–2076. <https://doi.org/10.1080/1042819031000119262>
- Shukla P, Singh R. Potential pharmacological interventions against hematotoxicity : an overview. *Expert Rev Hematol* 2015;1–10.
- Alifadiningrat, Dianira & Puspitasari, Dwiyantri & Hernaningsih, Yetti. (2022). Correlation Between Risk of Febrile Neutropenia Based on Rondonelli Score with Clinical Outcomes in Acute Lymphoblastic Leukemia Patients. *Indonesian Journal of Tropical and Infectious Disease*. 10. 62-68. 10.20473/ijt.v10i1.31916.
- Culakova E, Thota R, Poniewierski MS, Kuderer NM, Wogu AF, Dale DC, et al. Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. *Cancer Med* 2014;3(2):434–44. <https://doi.org/10.1002/cam4.200>.
- Weycker D, Barron R, Kartashov A, Legg J, Lyman GH. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. *J Oncol Pharm Pract* 2014;20(3):190–8. <https://doi.org/10.1177/1078155213492450>
- Huang, C., & Hsieh, T. (2020). Current strategies for managing febrile neutropenia in patients with cancer. *Supportive Care in Cancer*, 29(11),5983–5992. <https://doi.org/10.1007/s00520-020-05992-6>
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>
- International Agency for Research on Cancer. (2020). Indonesia: Cancer fact sheet. Global Cancer Observatory. <https://gco.iarc.who.int/media/globocan/factsheets/populations/60-indonesia-fact-sheet.pdf>



Alverde-Muñoz, K., & Ávila-Agüero, M. L. (2018). Neutropenia con cáncer: manejo en el servicio de emergencias [Febrile neutropenia in cancer patients: Management in the emergency room]. *Revista de Infectología*, 35(1), 62–71. <https://doi.org/10.4067/s0716100062>

Lacy, S. (2018). The management of febrile neutropenia in receiving chemotherapy: A review. *Current Oncology Reports*,

20(9)<https://doi.org/10/s-0-0737-5>

Lyman, G. H., Abella, E., & Pettengell, R. (2014). Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. *Critical Reviews in Oncology/Hematology*, 90(3), 190–199.

<https://doi.org/10.1016/j.critrevonc.2013.12.006>

Davis, A. E., Cloyd, J. M., & Garrison, A. (2021). Current treatment strategies for pancreatic cancer. *Cancer*, 13(3), 250.

<https://doi.org/10.3390/cancers13030250>

Müller, J., & Vasilenko, T. (2019). Current strategies for managing febrile neutropenia in patients with cancer. *Supportive Care in Cancer*, 27(9), 3233–3240.

<https://doi.org/10.1007/s00520-019-04740-2>

Lustberg, M. B. (2012). Management of neutropenia in cancer patients. *Clinical Advances in Hematology & Oncology*, 10(12), 825–826.

<https://doi.org/10.1186/1756-8722-5-405>

Gebremariam, G. T., Fentie, A. M., Beyene, K., & et al. (2022). Cost effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review. *BMC Health Services Research*, 22, 1600. <https://doi.org/10.1186/s12913-022-08933-z>

Siegel, R. L., Miller, K. D., & Jemal, A. (2020). *Cancer statistics, 2020*. CA: A Cancer Journal for Clinicians, 70(1), 7–30.

<https://doi.org/10.3322/caac.21590>

Crawford, J., Caserta, C., & Roila, F. (2020). Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. *Cancer Treatment Reviews*, 88, 102019. <https://doi.org/10.1016/j.ctrv.2020.102019>

National Cancer Institute. (2021). Chemotherapy. <https://www.cancer.gov/about-cancer/treatment/drugs/chemotherapy>

Hoeben, A., Joosten, E. A. J., & van den Beuken-van Everdingen, M. H. J. (2021). Personalized medicine: Recent progress in cancer therapy. *Cancers*, 13(2), 242. <https://doi.org/10.3390/cancers13020242>

Sullivan, D. R., & Bennett, K. L. (2015). Neutropenia in cancer patients: Current perspectives on diagnosis and management. *Clinical Advances in Hematology & Oncology*, 13(8), 574–583. <https://doi.org/10.1182/blood-2015-07-654019>

Punnapuzha, S., Edemobi, P. K., & Elmoheen, A. (2023). Febrile neutropenia. In *StatPearls*. StatPearls Publishing.

<https://www.ncbi.nlm.nih.gov/books/NBK541102/>

Molina, K. C. (2023). Best practices in the management of infectious complications for patients with cancer: Management of febrile neutropenia. *Journal of the Advanced Practitioner in Oncology*, 14(3), 201–206.

<https://doi.org/10.6004/jadpro.2023.14.3.4>



Febrile neutropenia prophylaxis with short- and long-acting colony-stimulating factors during treatment of solid tumours. *Clinical Practice*, 16(1), 9–13.

C. Y., & Tsai, P. S. (2019). Association between neutrophil to- tio and nutritional status in geriatric patients. *Journal of Laboratory Analysis*, 33(1), e22636.

<https://doi.org/10.1002/jcla.22636>

- Dziubek, K., & Twardowska, A. (2019). Febrile neutropenia: The role of prophylaxis and treatment. *Oncology in Clinical Practice*, 15(2), 72-77.
<https://doi.org/10.5603/OCP.2019.0035>
- Li, E., Schroeder, B. K., Campbell, D., Campbell, K., & Wang, W. (2021). The impact of baseline risk factors on the incidence of febrile neutropenia in breast cancer patients receiving chemotherapy with pegfilgrastim prophylaxis: A real-world data analysis. *Journal of Health Economics and Outcomes Research*, 8(1), 106–115.
- National Collaborating Centre for Cancer (UK). (2012). Neutropenic sepsis: Prevention and management of neutropenic sepsis in cancer patients (NICE Clinical Guidelines, No. 151). National Institute for Health and Clinical Excellence (NICE). Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK299128/>
- Curtis, B. R. (2017). Chemotherapy-induced febrile neutropenia. *Hematology: American Society of Hematology Education Program*, 2017(1), 187–193.
<https://doi.org/10.1182/asheducation-2017.1.187>
- Klastersky, J., et al. (2016). Febrile neutropenia: A new era. *European Journal of Cancer*, 68, 133-143. <https://doi.org/10.1016/j.ejca.2016.04.012>
- Morrison, T. J., et al. (2021). Pathophysiology of neutropenia and febrile neutropenia: A review. *Cancers*, 13(1), 50. <https://doi.org/10.3390/cancers13010050>
- Jodele, S., et al. (2017). The pathophysiology of febrile neutropenia in children with cancer. *Cancer*, 123(12), 2248-2259. <https://doi.org/10.1002/cncr.30629>
- Tzeng, Y. H., et al. (2017). Cytokine release syndrome in patients with febrile neutropenia: A comprehensive review. *International Journal of Hematology*, 106(4), 531-540. <https://doi.org/10.1007/s12185-017-2247-0>
- Gudiol, C., et al. (2020). Executive summary of the consensus document on the management of febrile neutropenia in patients with hematological malignancies. *Enfermedades Infecciosas y Microbiología Clínica*, 38(4), 174-181.
<https://doi.org/10.1016/j.eimc.2019.01.013>
- National Collaborating Centre for Cancer (UK). (2012, September). Neutropenic sepsis: Prevention and management of neutropenic sepsis in cancer patients. London: National Institute for Health and Clinical Excellence (NICE). PMID: 26065059.
- National Library of Medicine. (2004). Medical subject headings: Translation practices. In *Introduction to MeSH (NBK1533)*. National Center for Biotechnology Information (US). Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK1533/>
- Mhaskar, R., Clark, O. A. C., Lyman, G., Engel, A., Wang, H., & Djulbegovic, B. (2014). Colony-stimulating factors for chemotherapy-induced febrile neutropenia. *Cochrane Database of Systematic Reviews*, 2014(10), Article CD009031.
<https://doi.org/10.1002/14651858.CD009031.pub2>
- Boccia, R., Glaspy, J., Crawford, J., & Aapro, M. (2022). Chemotherapy-induced neutropenia and febrile neutropenia in the US: A beast of burden that needs to med? *Oncologist, 27*(8), 625–636.
[/10.1093/oncolo/oyac074](https://doi.org/10.1093/oncolo/oyac074)

